The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
Open accessAbstract
BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We analyzed its safety and efficacy in treatment of CD in a phase 2a study. METHODS: We conducted a double-blind, placebo-controlled study of 119 adults with moderate to severe CD failed by treatment with tumor necrosis factor antagonists. Patients were randomly assigned (1:1) to groups given MEDI2070 (700 mg) or placebo intravenously at weeks 0 and 4. Patients received open-label MEDI2070 (210 mg) subcutaneously every 4 weeks from weeks 12 to 112. The CD Activity Index was used to measure disease activity. RESULTS: The primary outcome, clinical response (either a 100-point decrease in CD Activity Index score from baseline or clinical remission, defined as CD Activity Index score <150) at week 8 occurred in 49.2% of patients receiving MEDI2070 (n = 59) compared with 26.7% receiving placebo (n = 60; absolute difference, 22.5%; 95% confidence interval, 5.6%-39.5%; P = .010). Clinical response at week 24 occurred in 53.8% of patients who continued to receive open-label MEDI2070 and in 57.7% of patients who had received placebo during the double-blind period and open-label MEDI2070 thereafter. The most common adverse events were headache and nasopharyngitis. Higher baseline serum concentrations of IL22, a cytokine whose expression is induced by IL23, were associated with greater likelihood of response to MEDI2070 compared with placebo. CONCLUSIONS: In a phase 2a trial of patients with moderate to severe Crohn's disease who had failed treatment with tumor necrosis factor antagonists, 8 and 24 weeks of treatment with MEDI2070 were associated with clinical improvement. ClinicalTrials.gov ID: NCT01714726.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17A has been shown to have a key pathogenic role in murine arthritis models.”
From TH17 cell heterogeneity and its role in tissue inflammation (2023) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L., Schreiber, S., Colombel, J., Rachmilewitz, D., Wolf, D. C., Olson, A. D., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,164
Self-citationDevelopment of a Crohn's Disease Activity Index
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · Gastroenterology · doi:10.1016/s0016-5085(76)80163-1 · Cited by 3,152
Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study.
Best, W. R., Becktel, J. M., Singleton, J. W., & Kern, F. (1976) · PubMed · Cited by 3,147
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K. P., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,819
Baumgart, D. C., & Sandborn, W. J. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60026-9 · Cited by 2,290
Colombel, J., Sandborn, W. J., Rutgeerts, P. J., Enns, R. A., Hanauer, S. B., Panaccione, R., Schreiber, S., Byczkowski, D., Li, J., Kent, J. D., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.11.041 · Cited by 2,239
Self-citationHanauer, S. B., Sandborn, W. J., Rutgeerts, P. J., Fedorak, R. N., Lukáš, M., MacIntosh, D. G., Panaccione, R., Wolf, D. C., & Pollack, P. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.030 · Cited by 1,711
Certolizumab Pegol for the Treatment of Crohn's Disease
Sandborn, W. J., Feagan, B. G., Stoinov, S., Honiball, P., Rutgeerts, P. J., Mason, D. H., Bloomfield, R., & Schreiber, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067594 · Cited by 1,141
Self-citationUstekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
Sandborn, W. J., Gasink, C., Gao, L.-L., BLANK, M. A., Johanns, J., Guzzo, C. A., Sands, B. E., Hanauer, S. B., Targan, S. R., Rutgeerts, P. J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203572 · Cited by 1,132
Self-citationMaintenance Therapy with Certolizumab Pegol for Crohn's Disease
Schreiber, S., Khaliq-Kareemi, M., Lawrance, I. C., Thomsen, O. Ø., Hanauer, S. B., McColm, J., Bloomfield, R., & Sandborn, W. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062897 · Cited by 1,039
Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
Sandborn, W. J., Rutgeerts, P. J., Enns, R., Hanauer, S. B., Colombel, J., Panaccione, R., D’Haens, G., Li, J., Rosenfeld, M. R., Kent, J. D., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00159 · Cited by 961
Self-citationComparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P. J., Feagan, B. G., Lichtenstein, G. R., Mayer, L., Schreiber, S., Colombel, J., Rachmilewitz, D., Wolf, D. C., Olson, A. D., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 942
Self-citationIL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn’s disease
Kobayashi, T., Okamoto, S., Hisamatsu, T., Kamada, N., Chinen, H., Saito, R., Kitazume, M. T., Nakazawa, A., Sugita, A., Koganei, K., et al. (2008) · Gut · doi:10.1136/gut.2007.135053 · Cited by 595
Andoh, A., Zhang, Z., Inatomi, O., Fujino, S., Deguchi, Y., Araki, Y., Tsujikawa, T., Kitoh, K., Kim‐Mitsuyama, S., Takayanagi, A., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.06.071 · Cited by 480
Schmidt, C., Giese, T., Ludwig, B., Mueller-Molaian, I., Marth, T., Zeuzem, S., Meuer, S. C., & Stallmach, A. (2005) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200501000-00003 · Cited by 279
Schmechel, S., Konrad, A., Diegelmann, J., Glas, J., Wetzke, M., Paschos, E., Lohse, P., Göke, B., & Brand, S. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20315 · Cited by 193
The interleukin‐23 axis in intestinal inflammation
Ahern, P. P., Ízcue, A., Maloy, K. J., & Powrie, F. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00705.x · Cited by 181
IL-22-mediated liver cell regeneration is abrogated by SOCS-1/3 overexpression in vitro
Brand, S., Dambacher, J., Beigel, F., Zitzmann, K., Heeg, M. H. J., Weiß, T. S., Prüfer, T., Olszak, T., Steib, C. J., Storr, M., et al. (2007) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00239.2006 · Cited by 126
Faubion, W. A., Fletcher, J. G., O’Byrne, S., Feagan, B. G., de Villiers, W. J. S., Salzberg, B. A., Plevy, S. E., Proctor, D. D., Valentine, J. F., Higgins, P., et al. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2013.354 · Cited by 108
Self-citationSandborn, W. J., Colombel, J., Schreiber, S., Plevy, S. E., Pollack, P. F., Robinson, A. M., Chao, J., & Mulani, P. M. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21328 · Cited by 80
Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease
Dige, A. K., Støy, S. H., Rasmussen, T. K., Kelsen, J., Hvas, C. L., Sandahl, T. D., Dahlerup, J. F., Deleuran, B. W., & Agnholt, J. S. (2012) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2012.06.015 · Cited by 62
Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
Cayatte, C., Joyce-Shaikh, B., Vega, F., Boniface, K., Grein, J., Murphy, E., Blumenschein, W. M., Chen, S., Malinao, M.-C., Basham, B., et al. (2012) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2012.2 · Cited by 55
Ge, M., Durham, L. K., Meyer, R. D., Xie, W., & Thomas, N. (2011) · Drug Information Journal · doi:10.1177/009286151104500409 · Cited by 39
Preclinical development of AMG 139, a human antibody specifically targeting IL ‐23
Köck, K., Pan, W., Gow, J. M., Horner, M. J., Gibbs, J. P., Colbert, A., Goletz, T. J., Newhall, K. J., Rees, W. A., Sun, Y., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12904 · Cited by 33
Self-citation
Cited by
Sorted by citations
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Lichtenstein, G. R., Loftus, E. V., Isaacs, K. L., Regueiro, M. D., Gerson, L. B., & Sands, B. E. (2018) · The American Journal of Gastroenterology · doi:10.1038/ajg.2018.27 · Cited by 1,424
Self-citationPathophysiology of Inflammatory Bowel Diseases
Chang, J. T. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2002697 · Cited by 1,295
Roda, G., Ng, S. C., Kotze, P. G., ARGOLLO, M. C., Panaccione, R., Spinelli, A., Kaser, A., Peyrin‐Biroulet, L., & Danese, S. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0156-2 · Cited by 1,111
Self-citationCytokine Networks in the Pathophysiology of Inflammatory Bowel Disease
Friedrich, M., Pohin, M., & Powrie, F. M. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.017 · Cited by 776
Targeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 723
Metadata
- Authors
- Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S., Higgins, P. D. R., Newbold, P., Faggioni, R., Patra, K., Li, J., Klekotka, P., Morehouse, C., Pulkstenis, E., Drappa, J., van der Merwe, R., & Gasser, R. A.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Western University (CA)
- University of Michigan (US)
- Amgen (United States) (US)
- Corresponding author
- Sands, Bruce E.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 153
- Issue
- 1
- Pages
- 77-86.e6
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2604523348
- Cited by
- 279
- References
- 26
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 25 · 2023: 36 · 2022: 35 · 2021: 34 · 2020: 35 · 2019: 50 · 2018: 40 · 2017: 5
- FWCI
- 23.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Gastroenterology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Zenodo (CERN European Organization for Nuclear Research) (public-domain)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- interleukin-23 inhibition, Crohn's disease, monoclonal antibodies, clinical response, clinical remission, CD activity index, IL-22, treatment safety, biologic therapy
- MeSH terms
- Interleukin-22, Adult, Antibodies, Monoclonal, Crohn Disease, Double-Blind Method, Female, Headache, Humans, Interleukins, Male, Middle Aged, Nasopharyngitis, Severity of Illness Index, Treatment Outcome, Retreatment, Interleukin-23, Young Adult, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
